IP Verse

Amicus Therapeutics competitive analysis

Latest patents of Amicus Therapeutics opposed by its competitors

Explore Amicus Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 16, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4114390
Dec 4, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene2
EP4176877
Dec 4, 2024Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease3
EP3914247
Nov 13, 2024Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry Disease3
EP4062916
Oct 9, 2024Methods Of Treating Fabry Patients Having Renal Impairment2
EP3840753
Jul 24, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene2
EP3630114
Nov 1, 2023Methods Of Treating Fabry Patients Having Renal Impairment1
EP3749308
Oct 25, 2023Treatment Of Patients With Classic Fabry Disease1
EP3432882
Sep 1, 2021Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The Gla Gene2
EP2683382
Apr 22, 2020Dosing Regimens For The Treatment Of Fabry Disease1

Latest publications and patents of Amicus Therapeutics New

Explore the latest publications and patents granted to Amicus Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Oct 10, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Amicus Therapeutics

EP4176877
Dec 4, 2024Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry DiseaseGranted And Under Opposition
EP4114390
Dec 4, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla GeneGranted And Under Opposition
EP3914247
Nov 13, 2024Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry DiseaseGranted And Under Opposition
EP4062916
Oct 9, 2024Methods Of Treating Fabry Patients Having Renal ImpairmentGranted And Under Opposition
EP3840753
Jul 24, 2024Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla GeneGranted And Under Opposition
EP3630114
Nov 1, 2023Methods Of Treating Fabry Patients Having Renal ImpairmentGranted And Under Opposition
EP3749308
Oct 25, 2023Treatment Of Patients With Classic Fabry DiseaseGranted And Under Opposition
EP3432882
Sep 1, 2021Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The Gla GeneGranted And Under Opposition
EP2683382
Apr 22, 2020Dosing Regimens For The Treatment Of Fabry DiseaseOpposition Rejected

Latest PTAB cases involving Amicus Therapeutics

Discover the latest PTAB cases involving Amicus Therapeutics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amicus Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 16, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMICUS THERAPEUTICS - 17 - -
BRAND MURRAY FULLER23 - - -
SANDOZ1171619 -
TEVA PHARMACEUTICALS20916 - 12